MGMT Promoter Methylation and Parathyroid Carcinoma.

Sara StorvallEeva RyhänenIlkka HeiskanenTiina VesterinenFrank V BenschJukka SchildtSoili KytöläAuli KarhuJohanna ArolaCamilla Schalin-Jäntti

Published in: Journal of the Endocrine Society (2019)

High MGMT promoter methylation status seems rare in PC. However, as demonstrated in other neuroendocrine tumors, some patients with disseminated PC might benefit from temozolomide. Demonstration of high methylation status could be a predictor of positive response to temozolomide treatment.

Keyphrases

dna methylation
neuroendocrine tumors
genome wide
gene expression
transcription factor
newly diagnosed
replacement therapy